| 1 |
33118484 | The putative binding site and SAR rationalization of small molecules against glucagon-like peptide-1 receptor using homology model and crystal structures: a comparative study. | 2022 Mar |
2 |
| 2 |
33895917 | Nutrients handling after bariatric surgery, the role of gastrointestinal adaptation. | 2022 Mar |
1 |
| 3 |
34381005 | Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. | 2022 Apr 1 |
1 |
| 4 |
34626851 | GLP-1 physiology informs the pharmacotherapy of obesity. | 2022 Mar |
2 |
| 5 |
34713962 | The incretin/glucagon system as a target for pharmacotherapy of obesity. | 2022 Feb |
1 |
| 6 |
34807465 | Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin. | 2022 Jan |
1 |
| 7 |
35048301 | Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. | 2022 Jan 19 |
1 |
| 8 |
35050311 | Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials. | 2022 Feb 1 |
1 |
| 9 |
35079845 | Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study. | 2022 May |
1 |
| 10 |
35134170 | Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants. | 2022 May 17 |
1 |
| 11 |
35208548 | The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. | 2022 Feb 2 |
1 |
| 12 |
35216451 | Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis. | 2022 Feb 20 |
1 |
| 13 |
35252207 | The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular. | 2022 |
1 |
| 14 |
35299971 | Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. | 2022 |
1 |
| 15 |
35370744 | GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events. | 2022 |
1 |
| 16 |
35391537 | GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. | 2022 Mar |
1 |
| 17 |
35395332 | Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis. | 2022 Apr 5 |
2 |
| 18 |
35399928 | The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. | 2022 |
1 |
| 19 |
35457152 | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. | 2022 Apr 14 |
2 |
| 20 |
35504854 | Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET). | 2022 Jul |
1 |
| 21 |
35537891 | Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. | 2022 Jun |
1 |
| 22 |
35546275 | Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study. | 2022 May 11 |
1 |
| 23 |
35559423 | Erratum: Influence of GLP-1 receptor agonist on insulin dosage and blood glucose control of patients with type 2 diabetes mellitus. | 2022 |
1 |
| 24 |
35608823 | Relationships of glucose, GLP-1 and insulin secretion with gastric emptying after a 75g glucose load in type 2 diabetes. | 2022 May 24 |
2 |
| 25 |
35616478 | Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment. | 2022 May-Jun |
1 |
| 26 |
35636559 | GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway. | 2022 Sep |
1 |
| 27 |
33045957 | Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors. | 2021 |
1 |
| 28 |
33067312 | Glucose Sensing Mediated by Portal Glucagon-Like Peptide 1 Receptor Is Markedly Impaired in Insulin-Resistant Obese Animals. | 2021 Jan |
9 |
| 29 |
33189580 | Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. | 2021 Apr |
1 |
| 30 |
33197271 | Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. | 2021 Jul 8 |
1 |
| 31 |
33236115 | Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. | 2021 Jan 23 |
1 |
| 32 |
33247879 | Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes. | 2021 Jun |
3 |
| 33 |
33272167 | Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management. | 2021 |
1 |
| 34 |
33300990 | Appetite-Regulating Hormones Are Reduced After Oral Sucrose vs Glucose: Influence of Obesity, Insulin Resistance, and Sex. | 2021 Mar 8 |
2 |
| 35 |
33308617 | Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies. | 2021 Jan |
1 |
| 36 |
33423388 | Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe? | 2021 Apr |
1 |
| 37 |
33444163 | HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. | 2021 Jan |
1 |
| 38 |
33477190 | Growth Promotion and Increased ATP-Binding Cassette Transporters Expression by Liraglutide in Triple Negative Breast Cancer Cell Line MDA-MB-231. | 2021 Jul |
2 |
| 39 |
33491111 | Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study). | 2021 Mar |
1 |
| 40 |
33534908 | Evidence for Glucagon Secretion and Function Within the Human Gut. | 2021 Apr 1 |
1 |
| 41 |
33540005 | Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. | 2021 Mar 15 |
1 |
| 42 |
33581878 | Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD. | 2021 Feb |
2 |
| 43 |
33594477 | Pharmacogenetics of novel glucose-lowering drugs. | 2021 Jun |
1 |
| 44 |
33631146 | The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in β-cells. | 2021 May |
1 |
| 45 |
33677922 | Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists. | 2021 Feb |
1 |
| 46 |
33681258 | Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/ mTOR/Caspase-3 and PI3K/Akt/GSK3β/Caspase-3 Signaling Pathways. | 2021 |
1 |
| 47 |
33684547 | Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis. | 2021 Jul |
1 |
| 48 |
33722838 | Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. | 2021 Jun |
1 |
| 49 |
33745782 | Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence. | 2021 Jun |
1 |
| 50 |
33759351 | Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients. | 2021 Jun |
1 |